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Abstract 
Purpose: This study examined the feasibility of sprint interval exercise training (SIT) for men 
with non-alcoholic fatty liver disease (NAFLD) and its effects on intrahepatic triglyceride 
(IHTG), insulin sensitivity (hepatic and peripheral), visceral (VAT) and subcutaneous 
adipose tissue (ScAT). 
Methods: Nine men with NAFLD (age 41±8 years; BMI 31.7±3.1 kg·m
-2
; IHTG 15.6±8.3%) 
were assessed at: 1) baseline 2) after a control phase of no intervention (pre-training) and 3) 
after six weeks of SIT (4-6 maximal 30 s cycling intervals, three times per week). IHTG, 
VAT and ScAT were measured using magnetic resonance spectroscopy or imaging and 
insulin sensitivity was assessed via dual-step hyperinsulinaemic-euglycaemic clamp with 
[6,6-D2] glucose tracer.  
Results: Participants adhered to SIT, completing ≥96.7% of prescribed intervals. SIT 
increased peak oxygen uptake (V̇O2 peak: +13.6% [95% CI: 8.8 to 18.2%]) and elicited a 
relative reduction in IHTG (-12.4% [-31.6 to 6.7%]) and VAT (-16.9% [-24.4 to -9.4%]; n=8), 
with no change in body weight or ScAT. Peripheral insulin sensitivity increased throughout 
the study (n=8; significant main effect of phase) but changes from pre- to post-training were 
highly variable (range: -18.5 to +58.7%) and not significant (P=0.09), despite a moderate 
effect size (g*=0.63). Hepatic insulin sensitivity was not influenced by SIT. 
Conclusions: SIT is feasible for men with NAFLD in a controlled laboratory setting and is 
able to reduce IHTG and VAT in the absence of weight loss.  
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List of abbreviations: 
NAFLD – non-alcoholic fatty liver disease 
SIT – sprint interval exercise training 
IHTG – intrahepatic triglyceride 
VAT – visceral adipose tissue 
ScAT – subcutaneous adipose tissue 
BMI – body mass index 
T2DM – type 2 diabetes mellitus 
HIIT – high intensity intermittent exercise training 
MR – magnetic resonance 
1
H-MRS – proton magnetic resonance spectroscopy 
EGP – endogenous glucose production 
HISI – hepatic insulin sensitivity index 
%EGPsupp – percentage suppression of EGP by low-dose insulin infusion 
V̇O2 peak – peak oxygen uptake 
HDL – high-density lipoprotein 
LDL – low-density lipoprotein 
TG – triglyceride 
NEFA – non-esterified fatty acids 
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HOMA-IR – homeostatic model assessment of insulin resistance 
Adipo-IR – adipose tissue insulin resistance index 
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Introduction 
Non-alcoholic fatty liver disease (NAFLD) is a common complication of obesity that is 
integrated in the pathogenesis of extra-hepatic comorbidities such as type 2 diabetes (T2DM) 
and cardiovascular disease (Byrne and Targher 2015). Insulin resistance is a central 
pathophysiological feature of NAFLD with associations between intrahepatic triglyceride 
content (IHTG) and insulin action in skeletal muscle, adipose tissue and the liver (Bril et al. 
2017). The prominence of these metabolic defects within the development and progression of 
NAFLD makes them priority targets for intervention.  
Lifestyle interventions, incorporating diet and physical activity, remain the cornerstone of 
treatment for NAFLD (Marchesini et al. 2016) and the importance of structured exercise 
within such interventions is underscored by both hepatic and extra-hepatic benefits. 
Continuous moderate-to-vigorous intensity exercise interventions increase cardiorespiratory 
fitness, reduce adiposity, improve peripheral insulin sensitivity, enhance cardiovascular 
function and improve circulating markers of metabolic health (Pugh et al. 2014; Hallsworth et 
al. 2015; Keating et al. 2015; Cuthbertson et al. 2016; Zhang et al. 2016). 
Guidelines for the management of NAFLD suggest that individuals undertake 150-200 min of 
moderate-intensity aerobic or resistance exercise each week, spread over three to five 
sessions (Marchesini et al. 2016). Observational evidence (Kistler et al. 2011) and 
experimental data (Cho et al. 2015; Oh et al. 2017) suggest that high-intensity exercise may 
be more potent in attenuating IHTG accumulation and NAFLD progression than moderate-
intensity exercise. This evidence is consistent with exercise intensity-dependent 
improvements in wider cardiometabolic outcomes, including indices of insulin sensitivity 
(Tjønna et al. 2008; Weston et al. 2013). Moderate-intensity exercise improves peripheral 
insulin sensitivity in patients with NAFLD (Cuthbertson et al. 2016) but evidence of its 
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impact on hepatic insulin sensitivity is unclear (Shojaee-Moradie et al. 2007; Cuthbertson et 
al. 2016). The effects of high-intensity exercise on hepatic and peripheral insulin sensitivity 
in individuals with NAFLD have not been assessed. A better understanding of these 
outcomes is important, given the link between IHTG, glycaemic control and metabolic 
disease (Byrne and Targher 2015; Marchesini et al. 2016; Bril et al. 2017). 
High-intensity intermittent exercise training (HIIT), which is characterised by repeated 
intervals of high-intensity exercise interspersed with periods of rest or low-intensity active 
recovery, has emerged as a form of exercise capable of providing many health benefits for 
individuals with, or at risk of, chronic disease (Gibala et al. 2012). Sprint interval training 
(SIT) is a version of HIIT consisting of brief bursts (30 s) of maximal-intensity exercise 
(Little et al. 2011). SIT induces adaptations in skeletal muscle which improve oxidative 
metabolism (Gibala et al. 2012) and, in some studies, enhances whole-body insulin sensitivity 
and glycaemic control (Richards et al. 2010; Cocks et al. 2015). These adaptations are likely 
to be of benefit for individuals with NAFLD, but the influence of SIT on IHTG and tissue-
specific (muscle, adipose tissue, liver) insulin sensitivity remains unknown. 
This study investigated the feasibility and efficacy of SIT as a therapeutic strategy in 
overweight or obese men with NAFLD. We sought to determine the effect of six weeks of 
SIT on IHTG, visceral (VAT) and subcutaneous adipose tissue (ScAT), as well as hepatic and 
peripheral (skeletal muscle and adipose tissue) insulin sensitivity. We hypothesised that SIT 
would reduce IHTG, VAT and ScAT, and increase insulin sensitivity. 
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Participant and Methods  
Ethical approval 
This study was approved by the research ethics committees of Loughborough University and 
the University of Nottingham and was conducted in accordance with the Declaration of 
Helsinki (World Health Organisation 2013). 
Participants 
Nine white European men were recruited from the general population and gave informed, 
written consent to participate. Although no power calculation was performed for this study, 
this sample size was chosen based on studies reporting significant improvements in 
cardiorespiratory fitness and indices of glycaemic control with HIIT (Little et al. 2011; Cocks 
et al. 2015). Eligibility criteria included inactive but weight-stable individuals aged 25 to 55 
years with a body mass index (BMI) between 27 and 40 kg·m
-2
 and a waist circumference ≥ 
94 cm. Participants were considered inactive if they did not complete any form of regular 
structured exercise.  Participants were identified as exhibiting NAFLD in that they had IHTG 
≥ 5.56%, determined during screening using magnetic resonance (MR) spectroscopy (1H-
MRS), and did not report excessive alcohol consumption (>21 units·week
-1
) or other 
secondary causes of hepatic steatosis (Marchesini et al. 2016). Participants were excluded if 
they: a) had any form of diagnosed chronic metabolic disease, b) were taking prescribed 
medications for hypertension, dyslipidaemia or glucose regulation or c) had contraindications 
to exercise or MR procedures.    
Study design 
This study utilised a repeated measures longitudinal design in which, following screening, 
participants completed two consecutive six week phases (control and SIT). The control phase 
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acted to monitor the variation in study outcomes over a similar period to that of the exercise 
intervention, but with participants maintaining their usual lifestyle. All participants completed 
the control phase followed by the exercise intervention, in order to avoid the confounding 
effects of detraining during the control phase. All study assessments were performed on 
consecutive days at baseline, pre-training and post-training: day 1) IHTG, VAT and ScAT; 
day 2) hepatic and peripheral insulin sensitivity and systemic metabolic biomarkers; day 3) 
cardiorespiratory fitness. Post-training assessments began 48 h after the final SIT session to 
eliminate the confounding influence of the final exercise training session on insulin 
sensitivity (Sylow et al. 2017). Dietary intake was standardised for 24 h before metabolic 
assessments through provision of all food and energy-containing drinks. This diet provided a 
balanced macronutrient profile and was tailored to each participant’s estimated energy 
requirement (Mifflin et al. 1990) using a  multiplication factor of 1.45 to account for the 
physical activity level of an inactive group (FAO et al. 2001). Participants were instructed 
and regularly reminded to maintain their usual lifestyle habits throughout both the control and 
SIT phases of the study. This included instructions to maintain dietary habits. Energy intake 
was not recorded due to concerns that monitoring may prompt dietary changes and given 
documented concerns regarding the accuracy of self-reported energy intake data (Dhurandhar 
et al. 2015). 
Imaging and Metabolic Assessments 
All metabolic assessments were performed after an overnight fast. MR measurements were 
performed on a Philips Achieva 3T system with 32 channel XL-Torso coil. IHTG was 
measured from a 20x20x20 mm voxel within the right lobe of the liver using 
1
H-MRS with 
Stimulated Echo Acquisition Mode (STEAM) localization (repetition time = 2046 ms) 
(Stephenson et al. 2013; Bawden et al. 2017). VAT and ScAT were assessed using a two-
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point modified Dixon technique (Philips) (Nakai et al. 2010) and an in-house algorithm to 
generate fat boundaries of visceral and subcutaneous regions.  
Hepatic and peripheral insulin sensitivity were assessed using a modified version of the 
hyperinsulinaemic, euglycaemic clamp with two stages of insulin infusion, low- (20 mU·m
-
2
·min
-1
) and high-dose (50 mU·m
-2
·min
-1
), each lasting 120 min. A continuous infusion of 
[6,6-D2] glucose tracer was initiated 120 min before the first hyperinsulinaemic stage and 
continued throughout for the quantification of endogenous glucose production (EGP) 
(Johnston et al. 2013). Blood glucose was clamped at 4.5 mmol·L
-1
 (coefficient of variation: 
mean (± SD) = 1.6 ± 0.9 and 2.7 ± 1.1 % at steady-state low- and high-dose insulin infusion, 
respectively).  
The hepatic insulin sensitivity index (HISI) (Matsuda and DeFronzo 1999) and the 
percentage suppression of EGP by low-dose insulin infusion (%EGPsupp) were calculated as 
indices of hepatic insulin sensitivity in the fasted and insulin-stimulated states, respectively. 
Peripheral insulin sensitivity was assessed as whole-body glucose uptake, which was 
assumed to be equal to the exogenous glucose infusion rate required to maintain euglycaemia 
at high-dose insulin infusion, during which EGP was negligible.  
Assessment of cardiorespiratory fitness and habitual physical activity 
Peak oxygen uptake (V̇O2 peak) and peak power output were measured using a ramped (+16 
Watt·min
-1
) cycling test on an electromagnetically-braked cycle ergometer (Excalibur Sport, 
Lode BV, The Netherlands) during which participants exercised until they were unable to 
maintain a pedalling cadence of 80 revolutions per min. V̇O2 was measured throughout 
(Metalyser 3B, Cortex Biophysik GmbH, Germany) and V̇O2 peak was determined as the 
highest value achieved across 15 s epochs (Robergs et al. 2010). V̇O2 peak and peak power 
output are presented as both absolute units (L·min
-1 and W) and relative to the participant’s 
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body weight (mL·kg
-1
·min
-1 
and W·kg
-1
). Participants were familiarised with this test one 
week before baseline assessments.  
To assess the impact of SIT on habitual physical activity levels, participants wore a tri-axial 
accelerometer (GT3x, Actigraph LLC, USA) for seven consecutive days before each 
assessment (baseline, pre-training and post-training). Data were analysed using computer 
software (Kinesoft 3.3.80, USA) (Troiano et al. 2008) and are presented as absolute minutes 
per day in each activity domain (sedentary time, light, moderate and vigorous physical 
activity) as well as percentages of accelerometer wear time.  
Exercise training 
Participants completed a SIT program consisting of three exercise sessions per week for six 
weeks. Sessions consisted of a low-intensity warm-up (5 min cycling at 50W), followed by 
30 s intervals of maximal sprint cycling on a stationary ergometer (Ergomedic 894E, Monark 
Exercise AB, Sweden), which was separated by periods of active recovery (4.5 min of low 
intensity cycling at 50W). The braking resistance of the ergometer was increased during 
intervals through the application of a load equivalent to 6.5% of lean body mass, determined 
using bioelectrical impedance analysis (BC-418, TANITA Europe BV, Amsterdam, The 
Netherlands). Participants were instructed to cycle ‘all-out’ during intervals whilst members 
of the research team provided verbal encouragement (Whyte et al. 2010). Four intervals were 
completed per session in the first two weeks with an additional interval added to each session 
every two weeks. Participants therefore completed 90 intervals over the six weeks of 
supervised training. 
Biochemical analyses 
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Plasma glucose isotope enrichment (atoms percent excess) was quantified as the 
oxime/trimethylsilyl derivative via gas chromatography mass spectrometry (GC-MS; 7890B, 
MSD 5977A; Agilent Technologies, UK) using selected ion monitoring of the ions at m/z 
319 and 321 (CV = 6.4%). Fasted circulating concentrations of total cholesterol, high-density 
lipoprotein (HDL), low-density lipoprotein (LDL), triglyceride (TG) and non-esterified fatty 
acids (NEFA) were analysed in plasma aliquots, collected before the start of 
hyperinsulinaemic euglycaemic clamps, by enzymatic colorimetric methods using a benchtop 
analyser (Pentra 400, HORIBA ABX Diagnostics, France) (All CV ≤ 1.5%). Serum insulin 
was quantified using radioimmunoassay (Millipore, USA) (CV = 7.3%), and HOMA-IR and 
Adipo-IR were calculated (Matthews et al. 1985; Gastaldelli et al. 2007). 
Tracer calculations 
Rates of EGP in the basal state and at low-dose insulin infusion were calculated (Wolfe and 
Chinkes 2005; Vella and Rizza 2009) accounting for non-steady-state during low-dose 
insulin infusion and assuming a fractional volume of distribution of 160 mL·kg
-1
.  
Statistical analyses 
Statistical analyses were performed using software (SPSS version 23.0, SPSS Inc., USA). All 
data were checked for normality of distribution prior to analysis. Normally distributed data 
are presented as mean with standard deviation (SD) and one-way repeated measures ANOVA 
was used to assess changes in outcomes across assessment visits (main effect of phase). The 
homogeneity of variance between data collected at each visit was assessed and a Greenhouse-
Geisser or Huynh-Feldt correction was applied, where appropriate. Statistically significant 
main effects were explored post-hoc using paired samples t-tests. Non-normally distributed 
data are presented as the median with interquartile range (IQR) and Friedman tests were used 
to assess the main effect of phase. Wilcoxon matched pairs tests were used for post-hoc 
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pairwise comparisons on non-normally distributed data. Probability (P-) values for post-hoc 
tests were adjusted using the Holm-Bonferroni correction (Holm 1979) to account for 
multiple comparisons. In text, the changes from pre- to post-training are presented as relative 
percentage change along with 95% confidence interval [CI] and effect size (adjusted Hedges’ 
g*). Cohen’s descriptors were used to interpret the magnitude of effect (Cohen 1988). For 
clarity, the change in IHTG is presented as both the absolute and relative percentage change. 
The association between changes in IHTG and whole-body glucose uptake from pre- to post-
SIT was assessed using Pearson’s bivariate correlation analysis. Statistical significance was 
accepted at P ≤ 0.05.   
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Results 
Participant characteristics and exercise training compliance 
All assessments made at baseline, pre- and post-training can be found in Table 1. The median 
self-reported alcohol intake of recruited participants was four units per week (range: 1 to 14). 
One participant was unable to attend hyperinsulinaemic, euglycaemic clamp assessments. All 
participants completed exercise training and attended all 18 sessions. Due to fatigue, one 
participant failed to complete two intervals in their first session and one interval in session 
two, but completed all prescribed intervals thereafter (total intervals: 87 = 96.7%).  
There were no significant differences in any measured outcome between baseline and pre-
training assessments, determined as a non-significant main effect of phase or, where 
appropriate, post-hoc comparison. However, from baseline to pre-training assessments, there 
was a tendency for increased fasted serum insulin and HOMA-IR, and reduced relative V̇O2 
peak (uncorrected P = 0.06, 0.07 and 0.07, respectively; all other outcomes P ≥ 0.13). 
 
Insert Table 1 here 
 
Effects of SIT on cardiorespiratory fitness and habitual physical activity 
Training improved absolute and relative V̇O2 peak by 11.2% [95% CI: 6.4 to 16.0%] (g* = 
0.83) and 13.6% [8.8 to 18.2%] (g* = 0.78; Figure 1a), respectively (P ≤ 0.001). This was 
alongside improvements in absolute (14.7% [10.7 to 18.7%], g* = 0.75) and relative (16.2% 
[11.1 to 21.2%], g* = 0.64; Figure 1b) peak power output (P ≤ 0.001). As outlined in Table 2, 
there were no differences in sedentary time or light, moderate or vigorous physical activity 
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throughout the duration of the study when analysed either as minutes per day or as a 
percentage of accelerometer wear time (main effect of phase: P ≥ 0.24). 
 
Insert Figure 1 here 
 
Effects of SIT on ectopic fat and systemic metabolic biomarkers  
Despite no change in body weight across study visits (main effect of phase: P = 0.17; Figure 
2a), SIT elicited a reduction in IHTG (P = 0.03; Figure 2b). From pre- to post-training, the 
mean absolute reduction was 2.1% [-3.4 to 0.8%], which equated to a relative reduction of 
12.4% [-31.6 to 6.7%] (g* = -0.23). One MR-image was found to be corrupted at the point of 
analysis so changes in VAT and ScAT are presented for n=8. These data do not correspond to 
the same eight individuals who completed the hyperinsulinaemic, euglycaemic clamp 
assessments. Training reduced VAT by 16.9% [-24.4 to -9.4%] (g* = -0.62, P = 0.02; Figure 
2c), but there were no changes in ScAT (main effect; P = 0.16; Figure 2d). Training increased 
circulating HDL by 8.4% [4.6 to 12.2%] (g* = 0.44, P = 0.02) but total cholesterol, LDL and 
triglycerides were unchanged throughout the study (P ≥ 0.19).  
 
Insert Figure 2 here 
 
Effects of SIT on peripheral and hepatic insulin sensitivity 
There was a significant main effect of phase for the increase in whole-body glucose uptake 
across the three study visits (P = 0.02; Figure 3a). However, responses to SIT were highly 
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variable between individuals (range: -18.5% to +58.7%; Figure 3b) and, despite a medium 
effect size (g* = 0.63), the change from pre- to post-training (18.1% [-3.0 to 39.2%]) was not 
statistically significant (unadjusted P = 0.09). There was an association between the change 
in IHTG and the change whole-body glucose uptake from pre- to post-training (r = -0.83, P = 
0.01). Basal EGP, HISI (Figure 3c) and %EGPsupp (Figure 3d) did not differ across study 
visits (P ≥ 0.37). 
Fasted blood glucose, plasma NEFA and Adipo-IR remained unchanged across the study 
visits (P ≥ 0.13). From pre- to post-training, fasted serum insulin (-13.9% [-24.9 to -2.9%], g* 
= -0.48, P = 0.04) and HOMA-IR (-16.6% [-27.5 to -5.6%], g* = -0.56, P = 0.02) were 
reduced. However, these reductions were similar in magnitude to the increases from baseline 
to pre-training (unadjusted P = 0.06 and P = 0.07, respectively) such that post-training values 
were no different from those measured at baseline (P ≥ 0.68). 
 
Insert Figure 3 here  
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Discussion 
The principal findings of this study are that a six-week SIT intervention is feasible for 
individuals with NAFLD and is well adhered to in a controlled laboratory setting. 
Furthermore, six weeks of SIT reduces IHTG and VAT in the absence of body weight change 
and, whilst hepatic insulin sensitivity appears to be unaffected, changes in peripheral insulin 
sensitivity are highly variable between individuals.  
This study reports almost perfect adherence to a six-week SIT intervention in nine individuals. 
Specifically, every participant completed the exercise programme, attending all 18 training 
sessions. Eight participants completed all 90 of the prescribed intervals whilst the remaining 
participant completed 87 intervals, with the three missing intervals contained within the first 
two training sessions. The implication is that individuals with NAFLD are able and willing to 
perform exercise training sessions composed of bursts of maximal exercise. This is important 
because observational evidence (Kistler et al. 2011) and experimental data (Cho et al. 2015; 
Oh et al. 2017) suggest that high-intensity exercise may be more potent in attenuating IHTG 
accumulation and NAFLD progression than moderate-intensity exercise. This SIT 
intervention may, therefore, represent a model of exercise that facilitates the completion of 
more intense exercise in individuals with NAFLD. This intervention was performed in a 
tightly controlled laboratory setting, with specialist equipment and where participants were 
individually supported by the research team. The participants recruited to this study were also 
screened thoroughly to ensure the absence of advanced cardiometabolic disease and may, 
therefore, not be representative of the majority of individuals with NAFLD. Given that the 
risk of an acute cardiac event during exercise is elevated in previously inactive individuals 
with established cardiometabolic disease (Thompson et al. 2007), the implementation of SIT 
requires additional scrutiny. The necessity for medical clearance and acclimatisation to 
exercise must be considered in this context (Riebe et al. 2015).  
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This study reports a mean absolute reduction in IHTG of 2.1% after six weeks of SIT in 
individuals with elevated IHTG (relative change from baseline: -12.4%). Previous studies 
employing aerobic and resistance exercise, combined or in isolation, report a reduction of 
similar magnitude (10 to 21%) in the absence of significant weight loss (Johnson et al. 2009; 
Hallsworth et al. 2011; Sullivan et al. 2012; Keating et al. 2015; Pugh et al. 2016; Houghton 
et al. 2017). However, greater reductions in IHTG (27 to 42%) have been reported when 
significant weight loss occurs as a result of exercise training (Hallsworth et al. 2015; Keating 
et al. 2015; Cuthbertson et al. 2016; Zhang et al. 2016). Therefore, whilst the independent 
effects of exercise on IHTG are recognised (Brouwers et al. 2016), the greatest benefits occur 
when exercise contributes to a negative energy balance. 
It was beyond the scope of this study to examine the mechanisms through which SIT reduced 
IHTG. However, habitual physical activity was consistent throughout and the energy 
expenditure elicited by SIT is low (Deighton et al. 2013). Therefore, whilst we did not 
measure energy intake, the absence of significant weight loss suggests that substantial energy 
restriction is unlikely to have occurred. Consequently, metabolic factors likely underpin the 
reported change in IHTG (Brouwers et al. 2016). Neither fasted circulating NEFA nor Adipo-
IR differed throughout the current study, suggesting that an improvement in adipose tissue 
insulin sensitivity in the fasted state is unlikely to be responsible for the reduction in IHTG 
with training. However, the possibility that changes in postprandial adipose tissue insulin 
sensitivity occurred cannot be dismissed (Brouwers et al. 2016). Circulating glucose 
stimulates hepatic de novo lipogenesis (Ameer et al. 2014) and, although fasted blood glucose 
was unchanged throughout the study, post-prandial glucose is likely to have been reduced in 
those with improved peripheral insulin sensitivity. Therefore, particularly in individuals who 
displayed improvements in whole-body glucose uptake, a reduction in hepatic de novo 
lipogenesis may have contributed to post-training reductions in IHTG (Linden et al. 2015). 
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Lastly, altered very low density lipoprotein metabolism is unlikely to be responsible for 
exercise-induced reductions in IHTG (Sullivan et al. 2012) but enhanced capacity to oxidise 
hepatic lipid is possible (Linden et al. 2015).  
Peripheral insulin sensitivity increased throughout this study but individual changes from pre- 
to post-SIT were highly variable and, despite a mean relative increase of 18.1% and a 
moderate effect size, this change was not significant. In obese but otherwise healthy men, 
four weeks (Cocks et al. 2015), but not two weeks (Whyte et al. 2010), of SIT increased 
peripheral insulin sensitivity. However, 15 to 20% of individuals may display minimal, or 
even adverse, responses after exercise training in outcomes related to glucose homeostasis 
(Stephens and Sparks 2015) and insulin sensitivity improved in only 10 out of 12 healthy 
individuals who completed a two-week SIT intervention, remaining unchanged in one and 
decreasing in another (Richards et al. 2010). This degree of variation in response to exercise 
is consistent with our findings where peripheral insulin sensitivity improved in 75% of 
participants after SIT, yet was reduced in 25%. Given this variation, a greater sample size 
may be required to detect significant differences in peripheral insulin sensitivity following 
SIT. A number of factors, including genetic polymorphisms, epigenetics and baseline 
participant characteristics, may impact on individual responses (Böhm et al. 2016). 
Neither basal nor insulin-stimulated hepatic insulin sensitivity are changed after six weeks of 
SIT. Our findings agree with data showing no change in hepatic insulin sensitivity after 12 
weeks of aerobic training in patients with NAFLD, despite significant reductions in body 
weight (Cuthbertson et al. 2016). EGP during low dose insulin infusion is reduced after 
aerobic or combined aerobic-plus-resistance exercise training in sedentary, healthy 
individuals and in patients with T2DM (Shojaee-Moradie et al. 2007; Meex et al. 2010). 
However, neither of these studies report changes in basal EGP or HISI, and the change at low 
dose insulin infusion reported by Meex et al. was no longer statistically significant when 
Page 20 of 30 
 
presented as %EGPsupp. EGP in both the basal state and during low dose insulin infusion was 
reduced in overweight, older women after a 9-month moderate-intensity aerobic exercise 
intervention (DiPietro et al. 2006). However, this may have been due to notably higher rates 
of EGP in this group at baseline compared to both the control group, and a separate group 
completing a higher-intensity exercise programme. The high-intensity exercise training had 
no effect on EGP in either the basal or insulin-stimulated states (DiPietro et al. 2006). The 
lack of improvements in hepatic insulin sensitivity in the current study may be due to 
insufficient intervention duration or because IHTG at the end of the intervention remained 
elevated (Cuthbertson et al. 2016). Hepatic insulin sensitivity, assessed as %EGPsupp, may be 
impaired with as little as 1.5% IHTG, with no further deterioration as IHTG increases (Bril et 
al. 2017). Post-training IHTG values in the present study ranged from 4.3 to 25.9% (mean 
12.4%).  
The favourable changes in IHTG, VAT, HDL and cardiorespiratory fitness in response to SIT 
are important for individuals with NAFLD. NAFLD is intricately related to the metabolic 
syndrome and associated with an elevated risk of T2DM, cardiovascular and renal disease 
(Byrne and Targher 2015). Ectopic lipid and dyslipidaemia are components of the metabolic 
syndrome and improvements in these risk factors are important in the treatment of NAFLD. 
Additionally, cardiorespiratory fitness is a marker of metabolic health and inversely 
associated with all-cause and cardiovascular mortality (Blair et al. 1989; Kodama et al. 2009). 
The large increase following SIT most likely reflects metabolic adaptations within skeletal 
muscle (Gibala et al. 2012), which may provide benefit via improved substrate metabolism 
(Rabøl et al. 2011; Brouwers et al. 2016). Collectively, the present study demonstrates the 
potential of SIT to elicit relevant metabolic improvements in men with NAFLD, but it is 
notable that the magnitude of response over this intervention was insufficient to re-establish 
values in an optimal range.  
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A strength of this study is the use of the most precise techniques available to assess key 
outcomes. Conversely, this study was conducted in a relatively small and homogenous 
sample of white European men with no other chronic metabolic disease. We may have lacked 
statistical power to detect differences in some of our outcomes following training and the 
findings of this study may not be generalisable to women, individuals of different ethnicity or 
those with metabolic co-morbidities. Furthermore, participants did not have a formal 
diagnosis of NAFLD so we have no information regarding disease severity. Whilst a 
randomised controlled trial design would be preferred, the inclusion of a control phase was 
chosen to monitor variation in study outcomes over a period of no intervention, whilst 
avoiding the additional recruitment of a non-exercise control group.  
In this study we have shown that men with NAFLD are compliant with SIT which, over six 
weeks, improves cardiorespiratory fitness and reduces IHTG and VAT, without altering body 
weight. Furthermore, changes in peripheral insulin sensitivity with training are highly 
variable between individuals, whilst hepatic insulin sensitivity remains unchanged. These 
results support the potential for interval-based, high-intensity exercise as an alternative to 
continuous moderate-intensity exercise in the management of NAFLD. However, larger 
RCTs are required to test the effectiveness of SIT in diverse populations, as well as its 
applicability in a clinical setting, sustainability over time and efficacy in individuals with 
advanced NAFLD.  
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Figure Legends 
Figure 1 – a) Peak oxygen uptake (V̇O2 peak) and b) peak power output measured at 
baseline, pre- and post-training. Data presented as mean ± SD (n=9). Outcomes presented 
relative to participant body weight. † indicates the difference between baseline and pre-
training values approached statistical significance (unadjusted P = 0.07); * indicates 
significantly different from pre-training value (P ≤ 0.001). 
 
Figure 2 – a) Body weight, b) intrahepatic triglyceride (IHTG), c) visceral adipose tissue 
(VAT) and d) subcutaneous abdominal adipose tissue (ScAT) measured at baseline, pre- 
and post-training. Data presented as mean ± SD. Data for body weight and IHTG are n=9. 
Data for VAT and ScAT are n=8. * indicates significantly different from pre-training value 
(P ≤ 0.03). 
 
Figure 3 – a-b) Peripheral and c) basal and d) insulin-stimulated hepatic insulin 
sensitivity measured at baseline, pre- and post-training. Data in ‘A’ and ‘D’ presented as 
mean ± SD (n=8). 
#Data in ‘C’ are not normally distributed and thus presented as median 
(IQR). Data in ‘B’ are % change from pre- to post-training measurements for each participant. 
 
Figure 1 Click here to download Figure Sargeant_revised Fig 1.tiff 
Figure 2 Click here to download Figure Sargeant_revised Fig 2.tiff 
Figure 3 Click here to download Figure Sargeant_revised Fig 3.tiff 
Table 1 - Participant characteristics and study outcomes 
 Baseline Pre-training Post-training 
P-value  
(main 
effect of 
phase) 
Effect size  
(Hedges’ g*) 
Baseline- 
Pre-
Training 
Pre- to 
Post-
Training 
Anthropometry          
  
 
Age (years) 41 ± 8          
BMI (kg·m-2) 31.7 ± 3.1          
Waist circumference (cm) 111.3 ± 7.5          
Body weight (kg) 102.5 ± 10.6 102.4 ± 10.1 101.2 ± 10.4 0.17 Trivial Trivial 
VAT (mL) (n=8) 1094 ± 238 1220 ± 395 995 ± 281 0.01 0.36 -0.62 
ScAT (mL) (n=8) 2801 ± 847 2800 ± 653 2658 ± 655 0.16 Trivial -0.21 
IHTG (%) 15.6 ± 8.4 14.4 ± 8.7 12.4 ± 8.2 0.001 Trivial -0.23 
Cardiorespiratory Fitness             
Absolute V̇Ȯ2 peak (L·min
-1) 3.23 ± 0.41 3.18 ± 0.41 3.53 ± 0.45c <0.001 Trivial 0.83 
Relative V̇Ȯ2 peak (mL·kg
-1·min-1) 31.8 ± 4.8 31.0 ± 4.7a 35.1 ± 5.4c <0.001 Trivial 0.78 
Absolute peak power output (W) 239 ± 42 237 ± 42 270 ± 43d <0.001 Trivial 0.75 
Relative peak power output (W·kg-1)  2.36 ± 0.49 2.34 ± 0.54 2.71 ± 0.57d <0.001 Trivial 0.64 
Insulin Sensitivity (n=8)             
Fasted serum insulin (mU·L-1) 17.6 ± 4.5 21.8 ± 8.1a 18.2 ± 6.0b 0.04 0.60 -0.48 
Fasted blood glucose (mmol·L-1) 4.7 ± 0.3 4.7 ± 0.4 4.5 ± 0.5 0.13 Trivial -0.32 
HOMA-IR 3.7 ± 1.0 4.5 ± 1.7a 3.7 ± 1.2b 0.03 0.59 -0.56 
Whole-body glucose uptake  
(mg·kg-1·min-1) 
5.2 ± 1.1 5.4 ± 1.1 6.4 ± 1.8e 0.02 Trivial 0.63 
Fasted plasma NEFA (mmol·L-1) 0.59 ± 0.15 0.55 ± 0.12 0.58 ± 0.19 0.83 -0.41 0.29 
Table 1
Adipo-IR* 52.7 (45.0 – 80.1)  69.3 (51.0 – 81.9)   55.4 (46.5 – 71.5) >0.99 0.38 -0.24 
Basal EGP (μmol·kg-1·min-1) 10.8 ± 1.5 10.7 ± 2.2 11.2 ± 2.1 0.70 Trivial 0.25 
HISI* (mg·m-2·min-1 per mU·L-1) 0.65 (0.56 – 0.74)   0.54 (0.52 – 0.60)   0.62 (0.58 – 0.69) 0.42 -0.47 0.34 
%EGPsupp (%) 59.9 ± 17.4 55.7 ± 11.3 51.6 ± 14.6 0.37 -0.28 -0.30 
Circulating Lipids             
Triacylglycerol (mmol·L-1) 2.2 ± 0.9 2.2 ± 0.7 1.9 ± 0.7 0.50 Trivial -0.35 
Total Cholesterol (mmol·L-1) 4.88 ± 0.59 4.80 ± 0.54 4.62 ± 0.75 0.19 Trivial -0.26 
HDL (mmol·L-1)* 0.90 (0.84 – 1.06)  0.88 (0.85 – 1.01)   0.95 (0.90 – 1.16)b 0.01 Trivial 0.44 
LDL (mmol·L-1) 2.85 ± 0.61 2.89 ± 0.54 2.77 ± 0.60 0.48 Trivial -0.21 
Data presented as mean ± SD and for n=9 unless otherwise stated. * indicates that data are not normally distributed and thus presented as median 
(IQR). a the difference between baseline and pre-training values approached statistical significance (uncorrected P-values; FPI P=0.06, HOMA-
IR P=0.07, Relative V ̇Ȯ2 peak P=0.07), b significantly different from pre-training values (P<0.05), c significantly different from pre-training 
values (P<0.01), d significantly different from pre-training values (P<0.001), e the difference between pre-training and post-training values 
approached statistical significance (uncorrected P=0.09); Trivial effect sizes were considered those of magnitude < 0.2; BMI: Body mass index; 
VAT: visceral adipose tissue; ScAT: subcutaneous abdominal adipose tissue; IHTG: intrahepatic triglyceride; V̇O2 peak: peak oxygen uptake; 
HOMA-IR: Homeostatic model assessment of insulin resistance; NEFA: Non-esterified fatty acids; Adipo-IR: Adipose tissue insulin resistance 
index; EGP: Endogenous glucose production; HISI: Hepatic insulin sensitivity index; %EGPsupp: Percentage suppression of EGP during low 
dose insulin infusion (20mU·m-2·min-1); HDL: High density lipoprotein; LDL: Low density lipoprotein. 
 
Table 2 – Habitual sedentary time and physical activity during baseline, pre- and post-training assessment periods 
 Baseline Pre-training Post-training 
P-value 
(main effect  
of phase) 
General           
Device wear time (minutes per day) 1027 ± 131 989 ± 119 1027 ± 166 0.68 
Counts per wear minute 293 ± 111 316 ± 156 294 ± 92 0.34 
Sedentary Behaviour           
Minutes per day 719 ± 92 693 ± 139 726 ± 155 0.77 
% of wear time# 70.3 (64.2 – 74.8) 74.9 (59.6 – 76.6) 66.5 (65.6 – 77.3) 0.37 
Light Activity           
Minutes per day 270 ± 74 256 ± 82 262 ± 59 0.60 
% of wear time 26.1 ± 5.5 26.0 ± 8.1 25.8 ± 5.5 0.93 
Moderate Activity           
Minutes per day# 23.0 (18.0 – 50.5) 31.0 (19.5 – 63.0) 30.0 (13.5 – 52.5) 0.89 
% of wear time# 2.4 (1.6 – 5.5) 2.7 (1.9 – 7.2) 2.5 (1.3 – 6.3) 0.24 
Vigorous Activity           
Minutes per day# 0.0 (0.0 – 2.0) 0.0 (0.0 – 1.5) 0.0 (0.0 – 1.5) 0.94 
% of wear time# 0.03 (0.00 – 0.18) 0.01 (0.00 – 0.13) 0.03 (0.00 – 0.13) 0.71 
Moderate-Vigorous Activity (MVPA)           
Minutes per day# 23.0 (18.5 – 55.0) 31.0 (19.5 – 67.0) 32.0 (13.5 – 59.0) 0.92 
% of wear time# 2.4 (1.7 – 6.1) 2.7 (1.9 – 7.8) 2.7 (1.3 – 7.1) 0.40 
Table 2
Data presented as mean ± SD, unless otherwise stated. n=9. #indicates that data are not normally distributed and thus presented as median (IQR).  
P-values represent the main effect of phase. 
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